ReviewJournal of physiology and biochemistry2026
Advances and challenges of ferroptosis in tumor immunity.
Review in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ferroptosis is a variant of regulated cell death elicited by iron dependent phospholipid peroxidation, represented for a robust therapy approach for the refractory tumor. In addition to kill cancer cells, ferroptosis could also elicited the immune response. The immunogenicity of ferroptosis resulted from both the immunogenicity of ferroptotic cell death and the effect of ferroptosis inducers on immune cells. The significantly varied susceptibility of immune cells to ferroptosis inducers may exert either enhance or inhibit cancer cells ferroptosis. Thus, the net immunomodulatory effect of ferroptosis may exhibit either immunostimulatory or immunoinhibitory. In this review, we firstly summarize immunogenicity of ferroptosis cancer cells. Then, we comprehensively and detailed discusses the versatile and complex ferroptosis immunomodulatory effective based crosstalk between cancer cells and various immune cells in the tumor microenvironment (TME), hoping to shed new light on novel strategies to promote immunotherapy efficacy by targeting ferroptosis.
Indexed as
Identifiers
41999522What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.